Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Acta Biomater. 2021 May 25;129:258–268. doi: 10.1016/j.actbio.2021.05.018

Figure 5. In vivo anticancer studies with PC-9/AR xenograft tumor model.

Figure 5.

(A) Change of tumor size in tumor-bearing nude mice received intravenous injection of different formulations. At the end of the study, isolated tumors were photographed (B) and weighted (C). Body weight of PC-9/AR tumor-bearing mice during the course of study (D). Results are mean ± SD (n=6). **, P < 0.01; ***, P < 0.001, compared with control and monotherapy groups.